Royal Bank of Canada’s Zhengye Biotechnology Holding ZYBT Stock Holding History

Royal Bank of Canada’s Portfolio ZYBT Stock Details ZYBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1K	Hold	1,230	–	–	﹤0.01%	7300
2026 Q1	$1K	Buy	1,230 +847	+221%	+$793	﹤0.01%	6999
2025 Q4	$0	Buy	+383	New	+$849	﹤0.01%	7793
2025 Q3	–	Sell	-34	Closed	–	–	7651
2025 Q2	$0	Buy	+34	New	+$270	﹤0.01%	7458

Other funds holding ZYBT

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Royal Bank of Canada's ZYBT Position: Q2 2026 in Review

Royal Bank of Canada held its Zhengye Biotechnology Holding (ZYBT) position steady in Q2 2026 at 1,230 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #7300.

Royal Bank of Canada first reported a position in ZYBT in Q2 2025 and has held it in 4 quarters since. 8 funds tracked by Wall St. Rank hold ZYBT as of Q2 2026.

Royal Bank of Canada held 1,230 shares of Zhengye Biotechnology Holding worth $1K as of Q2 2026.
Royal Bank of Canada left its Zhengye Biotechnology Holding share count unchanged in Q2 2026.
Zhengye Biotechnology Holding made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #7300 holding.
Royal Bank of Canada first reported a position in Zhengye Biotechnology Holding in Q2 2025 and has held it in 4 quarters since.
8 funds tracked by Wall St. Rank held Zhengye Biotechnology Holding as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.